Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

Zarxio

filgrastim
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Neupogen SOLUTION, INJECTABLE 480 mcg/1.6 mL, 300 mcg/mL    
Neupogen SOLUTION, INJECTABLE 600 mcg/mL    
Granix SOLUTION, SUBCUTANEOUS 300 mcg/0.5 mL, 480 mcg/0.8 mL    
Nivestym SOLUTION, SUBCUTANEOUS 300 mcg/0.5 mL, 480 mcg/0.8 mL    
Releuko SOLUTION, SUBCUTANEOUS 300 mcg/0.5 mL, 480 mcg/0.8 mL    
Zarxio SOLUTION, SUBCUTANEOUS 300 mcg/0.5 mL, 480 mcg/0.8 mL    
VIEW MORE Hematopoietic Agents
CLASS
201600
Comments:

New FDA Indications

Neupogen, Zarxio, Nivestym, Releuko, and Granix have all been classified as therapeutically equivalent and should be interchanged in a 1:1 ratio at the same dosing interval based on the lowest cost agent at the time.

Nivestym is the preferred product for adult and pediatric inpatient and outpatient use (updated March 2024)

 

Dose rounding (Adults):

  • Patients < 75 kg: 300 mcg dose
  • Patients > 75 kg: 480 mcg dose

 

Reviewed: 26 January 2016, 25 Sept 2018 (Nivestym), Sept. 2022 (Releuko)

Updated: December 2022 (Dose Rounding)

Filgrastim-pbbk (Releuko)

Last updated: Mar. 25, 2024
  • Therapeutic Interchange






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved